Scalp cooling is a proven approach to reduce chemotherapy-induced alopecia that has been used successfully by thousands of patients worldwide for decades. Reduced temperature results in a decreased blood flow to the scalp area so that less chemotherapy reaches the hair cells. Therefore, hair cells are not exposed to the full dose of chemotherapy and may be able to survive the chemotherapy treatment. As a result, hair is less likely to fall out.
Two physiologic reactions occur during scalp cooling:
1. Reduced blood flow
Vasoconstriction in the scalp area limits the amount of chemotherapy agent delivered to the hair follicles.
2. Reduced metabolism
Lower scalp temperature decreases the reaction rate causing normal cellular activity in the localized scalp area to slow dramatically.
With these two reactions the follicles absorb fewer chemotherapy agents and hair loss is significantly reduced.

Scalp cooling requires a 30-minute pre-infusion cooling time. Following a patient’s infusion, the chemotherapy agent is still active in the patient’s bloodstream. Therefore, the scalp cooling treatment continues for a cycle of post-infusion cooling. Depending on drug and dose, this is typically 60–180 minutes.

A patient’s hair can be a major part of their identity, and many patients rate hair loss as one of the most devastating side effects of chemotherapy. Chemotherapy-induced alopecia is an unwelcome reminder of disease, one that can negatively affect self-image, confidence, overall sense of well-being and a patient’s attitude toward treatment.
Hair loss is no longer inevitable. The DigniCap Scalp Cooling System is a proven approach to reduce chemotherapy-induced alopecia, used successfully by thousands of patients worldwide to maintain privacy, self-esteem and control during a critical period of treatment.

Pivotal Trial – Clinical Study in Stage I and II Breast Cancer
In 2015, after a rigorous review by the FDA, DigniCap was the first scalp cooling system to receive clearance in the United States. Summary It was concluded that the DigniCap Scalp Cooling System prevented hair loss in 66.3% of patients with breast cancer receiving adjuvant chemotherapy, compared to a control group where all patients experienced significant hair loss. Scalp cooling treatment was well-tolerated and no scalp metastases have been observed.
Anthracyclines
An Italian study published in 2019 assessed the effectiveness of scalp cooling with DigniCap for patients receiving adjuvant chemotherapy with an anthracycline with or without taxanes. DigniCap was able to prevent significant hair loss in 43% of breast cancer patients receiving adjuvant chemotherapy.
Research Overview – Solid Tumors
As published in numerous academic journals, The DigniCap Scalp Cooling System has been shown to be safe and effective in reducing chemotherapy-induced alopecia in cancer patients with solid tumors.
Of 226 patients with various solid tumors and undergoing different chemotherapies 65% showed no visible hair loss.
Research Overview – Scalp Metastases
Metastasis occurs when cancer spreads to other parts of the body. Some patients have asked whether scalp cooling increases the chance of metastases in the scalp.
A study published in 2017 reviewed patients with breast cancer receiving chemotherapy while using scalp cooling for hair preservation and found there was no statistical difference in the incidence of scalp metastasis between patients using scalp cooling vs. no scalp cooling. The study concluded that “based on this extensive review and meta-analysis, scalp cooling is highly unlikely to increase the incidence of scalp metastases in patients with early-stage breast cancer receiving adjuvant chemotherapy.”

To help prevent chemotherapy drugs from reaching the hair follicles, DigniCap cools the scalp to approximately 2–6°C. The exact treatment temperature is adjusted based on the patient’s hair thickness. Most patients tolerate scalp cooling with The DigniCap Scalp Cooling System very well. Your doctor can provide a pain reliever if you develop a headache. A warm drink and blanket can also help during treatments.

Indication for Use
The DigniCap Scalp Cooling System is indicated to reduce the likelihood of chemotherapy-induced alopecia in cancer patients with solid tumors.
Intended Use
A cooling device intended to reduce or prevent the frequency and severity of alopecia during chemotherapy in which alopecia inducing chemotherapy agents are used.
Contraindications
The use of DigniCap is contraindicated in pediatric patients.
The use of DigniCap is contraindicated in adult patients with:
Almost everyone can expect to experience some degree of hair loss during chemotherapy. Scalp cooling is an effective method for reducing the risk of chemotherapy-induced hair loss in men and women with solid tumor cancers. The outcome is dependent on several factors including the chemotherapy regimen, dose, duration of drug infusion, chemotherapy drug metabolism and other medical considerations.
DigniCap offers the chance to minimize chemotherapy induced hair loss for men and women with solid tumor undergoing chemotherapy. Most patients who use DigniCap will see a significant reduction in the amount of hair loss from chemotherapy. However, shedding should be expected and is normal for patients using scalp cooling. The amount of shedding experienced will vary from patient to patient.
Chemotherapy may cause scalp irritation, make the hair dry, brittle, and more difficult to manage. Handling your hair gently during treatment and for several months after you complete your chemotherapy regimen may help reduce the amount of shedding and maintain your hair quality.
Washing Your Hair
Styling Your Hair
Avoid Chemicals
Hair Shedding
Hair Matting
Hair Care After Treatment
The goal of scalp cooling is to reduce overall hair loss so that a wig, cap, scarf or other head covering is not needed.